Company
Acro Biomedical
Last checked: Nov 20, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations
FDA decisions since 2015
4
510(k), De Novo and PMA
Device trials
1
As lead sponsor, any status
Adverse event reports
0
Received Nov 1, 2025 to Nov 20, 2026
Recall records
0
One per recalled product
This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.
Financing
Public company. Figures from its SEC financial statements.
Listed
ACBM
OTC · ACRO BIOMEDICAL CO., LTD.
Public float
$21K
Value of shares held by non-insiders on Jun 30, 2025
Revenue
$0
Fiscal year ending Dec 31, 2025
Net income
-$101K
Fiscal year ending Dec 31, 2025
R&D spending
$0
Fiscal year ending Dec 31, 2024
Cash
$4K
As of Jun 30, 2026
Long-term debt
Not reported
Shares outstanding
60.0M
As of Aug 5, 2026
Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.
Investors
5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.
No 5%+ shareholder filings or SBIR grants found under the name Acro Biomedical.
Latest FDA decisions
K233378 · Decided Oct 18, 2024 · 382 days after receipt
Device type: Wound Dressing With Animal-Derived Material(S) (KGN) · General & Plastic Surgery
- ABCcolla Bone Matrix510(k)
K212156 · Decided Oct 8, 2021 · 88 days after receipt
Device type: Filler, Bone Void, Calcium Compound (MQV) · Orthopedic Surgery
- ABCcolla Bone Graft510(k)
K171629 · Decided Feb 1, 2018 · 244 days after receipt
Device type: Filler, Bone Void, Calcium Compound (MQV) · Orthopedic Surgery
1 more FDA decisions with a free account
Device trials
Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.
NCT04054817 · 6 participants · Start Nov 2, 2020 · Primary completion Oct 5, 2022
Device: Lamellar keratoplasty-ABCcolla® Collagen Ophthalmic Matrix · For: Corneal Ulcer
Sites: Kaohsiung City, Taiwan; Taipei, Taiwan · 3 sites in all
Reports received
0
Received Nov 1, 2025 to Nov 20, 2026
Malfunction reports
0
Injury reports
0
Death reports
0
Adverse event reports received per month
Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.
No reports to chart for this view.
Device types named most often
Last 12 months, by FDA product code. A company that sells more gets more reports.
No device types to rank.
Brand names named most often
Last 12 months, as written on the reports. One product can appear under several spellings.
No brand names to rank.
Recent recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recalls under this name in FDA's data.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.